Diagnostic News and Research

RSS

New diagnostic approach for Lyme disease

George Mason University researchers can find out if a tick bite means Lyme disease well before the bite victim begins to show symptoms.

25 May 2012

$IOF report predicts dramatic rise in osteoporosis-related fractures in Brazil$

IOF report predicts dramatic rise in osteoporosis-related fractures in Brazil

A new Audit report on fragility fractures, issued today by the International Osteoporosis Foundation (IOF), predicts that Brazil will experience an explosion in the number of fragility fractures due to osteoporosis in the coming decades.

25 May 2012

$Fragility fractures predicted to more than double in Latin America$

Fragility fractures predicted to more than double in Latin America

The International Osteoporosis Foundation (IOF), in cooperation with medical and patient societies from throughout Latin America, has today published a landmark report which compiles osteoporosis-related data on 14 countries and the region as a whole. The report shows that fragility fractures due to osteoporosis are predicted to more than double in some countries in the coming decades.

25 May 2012

Study reveals why people develop life-threatening drug allergies

A research team led by the University of Melbourne and Monash University, Australia, has discovered why people can develop life-threatening allergies after receiving treatment for conditions such as epilepsy and AIDS.

25 May 2012

Breakthrough in understanding the causes of unexplained male infertility

The diagnosis of male fertility is usually performed through the observation of the sperm in the microscope. However, a normal quality semen does not guarantee an adequate fertility. In fact, there is a considerable proportion of cases of unexplained infertility and data suggest that abnormal sperm function may have a genetic or molecular origin.

24 May 2012

Halo Healthcare acquires assets of NeoMatrix

Halo Healthcare, Inc. announces it has acquired the assets of NeoMatrix, LLC and has restructured the Company, including engaging a new CEO and management team, appointing a new Board of Directors, and relaunching the HALO diagnostic device for breast cancer risk assessment.

24 May 2012

Cepheid’s Xpert CT/NG system receives European CE marking

Cepheid today announced that both Xpert CT/NG and Xpert CT have received CE marking, with shipments expected to begin immediately.

24 May 2012

Preliminary results from Celldex’s CDX-011 Phase 2b breast cancer study

Celldex Therapeutics, Inc. today announced preliminary results from the Company's randomized Phase 2b EMERGE study of CDX-011 (glembatumumab vedotin) antibody drug conjugate in patients with glycoprotein NMB (GPNMB) expressing, advanced, heavily pretreated breast cancer. Preliminary results suggest that CDX-011 induces impressive response rates compared to current, available therapies in patients with advanced, refractory breast cancers with high GPNMB expression.

24 May 2012

LabCorp, XDx partner to develop and commercialize SLE flare predictor test

XDx, Inc. announced today that it has entered into a collaboration and license agreement with Laboratory Corporation of America Holdings (LabCorp)whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus.

24 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

Mimotopes can help develop new diagnostic tests for sleeping sickness

Each year many thousands of Africans contract sleeping sickness. The cause is a unicellular parasite, a trypanosome, which is transmitted by the bite of tsetse flies. First the parasite multiplies in blood and lymph, while evading the human immune system. It then lodges in organs like heart and kidneys and finally in the brain. Patients become disoriented, their sleeping pattern disintegrates and they get motor and mental problems.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

Researchers identify novel biomarkers that could confirm exposure to radiation

Researchers at the Medical College of Wisconsin have identified novel biomarkers that could be used to confirm exposure to damaging radiation in large groups of people potentially exposed to unknown and variable doses for the purpose of triage and treatment.

23 May 2012

Special feature of Science journal highlights protein array technology

A special feature in this week's issue of the journal Science highlights protein array technology, touching on research conducted by Joshua LaBaer, director of the Biodesign Institute's Virginia G. Piper Center for Personalized Diagnostics.

23 May 2012

New evidence behind WOUNDCHEK Protease Status to be presented at EWMA conference

New evidence behind the world's first point of care wound diagnostic test, WOUNDCHEK Protease Status, to be presented at the European Wound Management Association (EWMA)'s conference in May 2012 confirms the importance of protease activity in wound healing and wound assessment, quantifies elevated protease activity (EPA), and also presents preliminary results on testing for and treating EPA in clinical practice.

22 May 2012

Intermountain signs collaborative research agreement with Myriad

Intermountain Healthcare and Myriad Genetics today announced they have signed a collaborative research agreement. The purpose of this agreement is to perform research and validation studies on transformative molecular diagnostic tests being developed by Myriad in an effort to improve the care and treatments for patients at Intermountain and around the world.

22 May 2012

Laxative free bowel prep visualized on Viatronix V3D-Colon platform

Viatronix Incorporated, a leading innovator and developer of 2D/3D medical imaging and diagnostic software today announced that their V3D-Colon platform was exclusively used to perform a key study recently published in the Annals of Internal Medicine.

21 May 2012

HCCI's report shows facility prices outpaced general inflation for the privately insured under 65

Rising prices for care were the chief driver of health care costs for privately insured Americans in 2010, according to the first report from the newly formed Health Care Cost Institute.

21 May 2012

First study to test safety of quantum dots in primates

A pioneering study to gauge the toxicity of quantum dots in primates has found the tiny crystals to be safe over a one-year period, a hopeful outcome for doctors and scientists seeking new ways to battle diseases like cancer through nanomedicine.

21 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012